The impact of hepatitis C burden: an evidence‐based approach
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Background: Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertaining to screening for HCV by the Centers for Disease Control and Prevention and newer treatment regimens with high efficacy, short duration and the potential for interferon‐free therapies, have energised the health care practitioners regarding HCV management. Aim: To assess the full impact of HCV burden on clinical, economic and patient‐reported outcomes. Methods: An expert panel was convened to assess the full impact of HCV burden on a number of important outcomes using an evidence‐based approach predicated on Grading of Recommendations Assessment, Development and Evaluation methodology. The literature was summarised, graded using an evidence‐based approach and presented during the workshop. Workshop presentations were intended to review recent, relevant evidence‐based literature and provide graded summary statements pertaining to HCV burden on topics including the relationships between HCV and the development of important outcomes. Results: The associations of HCV with cirrhosis, HCC, liver‐related mortality, type 2 diabetes mellitus, rheumatological diseases and quality of life impairments are supported by strong evidence. Also, there is strong evidence that sustained viral eradication of HCV can improve important outcomes such as mortality and quality of life. Conclusions: The current evidence suggests that HCV has been associated with tremendous clinical, economic and quality of life burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-5-201309030-00672 · Cited by 475
Goodgame, B., Shaheen, N. J., Galanko, J., & El-Serag, H. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07678.x · Cited by 72 · cited 1×
“tematic review of 21 cohort studies revealed that the time to HCC in patients with HCV ranged between 17 and 31 years, the 30 year risk ranged between 0% and 3%, and the mode of acquisition associated with the highest risk was recipients of blood (1 per 1000).(36) In a”
BackgroundSelf-citation
Cited by
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Manns, M. P., Buti, M., Gane, E., Pawlotsky, J.-M., Razavi, H., Terrault, N., & Younossi, Z. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.6 · Cited by 506
Self-citationYounossi, Z., Park, H., Henry, L., Adeyemi, A., & Stepanova, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.039 · Cited by 400
Self-citationGlobal epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
Self-citationKwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., Felizarta, F., Sulkowski, M. S., Gane, E., Maliakkal, B., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.039 · Cited by 302
Self-citationSimmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ396 · Cited by 261
Golabi, P., Fazel, S., Otgonsuren, M., Sayiner, M., Locklear, C. T., & Younossi, Z. M. (2017) · Medicine · doi:10.1097/md.0000000000005904 · Cited by 257
Self-citationApplication of Dendrimers for the Treatment of Infectious Diseases
Mhlwatika, Z., & Aderibigbe, B. A. (2018) · Molecules · doi:10.3390/molecules23092205 · Cited by 97
“Approximately 80% of patients with hepatitis C develop chronic liver infection [78].”
BackgroundHCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients
Bajaj, J. S., Sterling, R. K., Betrapally, N. S., Nixon, D. E., Fuchs, M., Daita, K., Heuman, D. M., Sikaroodi, M., Hylemon, P. B., White, M. B., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13732 · Cited by 63
Metadata
- Authors
- Younossi, Z. M., Kanwal, F., Saab, S., Brown, K. A., El‐Serag, H. B., Kim, W. R., Ahmed, A., Kugelmas, M., & Gordon, S. C.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-01-26
- Volume
- 39
- Issue
- 5
- Pages
- 518-531
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2032095674
- Cited by
- 117
- References
- 3
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.